Acorda Therapeutics

Acorda Therapeutics, Inc.
TypePublic
Industry
Founded1995 (1995)
FounderRon Cohen
Headquarters420 Saw Mill River Road, Ardsley, New York,
United States
Key peopleRon Cohen (CEO)
Products
RevenueDecrease US$192.408 million (2019)
Negative increase US$−311.632 million (2019)
Negative increase US$−272.966 million (2019)
Total assetsDecrease US$799.718 million (2019)
Total equityDecrease US$310.820 million (2019)
Number of employees
344 (2020)
Websiteacorda.com

Acorda Therapeutics, Inc. is an American biotechnology company based in Pearl River, New York. The company develops therapies that improve neurological function in people with Parkinson's disease, multiple sclerosis and other neurological disorders. Acorda Therapeutics manufactures and markets the drugs Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine) in the United States.